BPC-157 (Body Protection Compound-157, pentadecapeptide GEPPPGKPADDAGLV, MW 1419.5 Da) was originally isolated as a fragment of the human gastric juice protein BPC. Its preclinical research profile spans over three decades of rodent studies examining tissue repair, angiogenesis, anti-inflammatory signaling, and gastrointestinal cytoprotection. This compendium summarizes key study designs, dosing parameters, model systems, and quantified endpoint data from the published preclinical literature to provide a consolidated mechanistic and empirical reference for investigators.
Gastrointestinal and Mucosal Models: Study Design and Endpoint Data
BPC-157's original preclinical characterization centered on gastrointestinal cytoprotection. In ethanol-induced gastric lesion models in Wistar rats, BPC-157 at 10 µg/kg intraperitoneal produced a statistically significant reduction in total lesion area (approximately 55–65% reduction versus vehicle, p<0.001), with comparable efficacy observed via oral administration at 10 µg/kg and 10 ng/kg — demonstrating activity across a broad dose range spanning several orders of magnitude. In NSAIDs-induced intestinal damage models, BPC-157 at 2 µg/kg reduced macroscopic intestinal lesion scores by approximately 50% (p<0.01). Colitis models using DSS in rats showed histopathological scores (crypt integrity, mucosal erosion, inflammatory infiltrate) significantly improved at day 7 with BPC-157 at 2–10 µg/kg intraperitoneal (p<0.05). The mechanism of gastrointestinal protection involves upregulation of cytoprotective prostaglandins, EGF receptor activation, and NF-κB suppression in intestinal epithelial cells.
Tendon, Ligament, and Muscle Repair: Dosing Parameters and Functional Endpoints
BPC-157 in Achilles tendon transection models (Sprague-Dawley and Wistar rats) has been studied at 2 µg/kg and 10 µg/kg intraperitoneal, with treatment initiated 30 minutes post-surgery and continued for 14 days. Functional endpoints assessed included histological collagen fiber organization, tendon continuity score, and biomechanical breaking strength testing at day 14. At 10 µg/kg, breaking strength was approximately 40% greater in treated versus vehicle controls (p<0.01); collagen fiber organization scoring showed 60–70% of treated tendons reaching "organized" classification versus 25–30% in vehicle controls. In medial collateral ligament (MCL) transection models, BPC-157 at 10 µg/kg significantly improved ligament healing scores at day 14 versus vehicle (p<0.05). In muscle crush injury models (Wistar rats), BPC-157 at 10 µg/kg intraperitoneal demonstrated accelerated myofiber regeneration — increased MyoD-positive satellite cells and reduced central nuclei proportion at day 7 versus vehicle (p<0.05).
VEGFR2, FAK/Paxillin, and Angiogenic Signaling: Molecular Mechanism Data
The molecular mechanism studies supporting BPC-157's tissue repair activity converge on the VEGFR2 signaling axis. In healing tendon tissue from BPC-157-treated rats, VEGFR2 mRNA expression was elevated approximately 2.1-fold versus vehicle by qRT-PCR (p<0.05). In vitro studies in human tendon fibroblasts confirmed BPC-157 at 1–100 ng/mL activated FAK phosphorylation (Tyr397) — approximately 1.8-fold above vehicle (p<0.05) — and downstream paxillin phosphorylation (Tyr118), consistent with integrin-mediated adhesion complex formation and pro-migratory signaling. PI3K/Akt phosphorylation (phospho-Akt Ser473) was elevated approximately 1.7-fold in BPC-157-treated fibroblast lysates, providing an anti-apoptotic and proliferative signal. MAPK/ERK1/2 phosphorylation was elevated approximately 1.6-fold above vehicle (p<0.05). In HUVEC tube formation assays, BPC-157 at 10–100 ng/mL increased total tube length by approximately 55% and branching points by approximately 45% versus vehicle (p<0.01).
Anti-Inflammatory and NF-κB Suppression Data
In carrageenan-induced paw edema in rats, a model for acute-on-chronic prostaglandin-mediated inflammation, BPC-157 at 10 µg/kg intraperitoneal produced approximately 30% edema reduction at 4h post-carrageenan injection versus vehicle (p<0.05), comparable in magnitude to a 10 mg/kg ibuprofen reference control in the same model. In LPS-challenged macrophage cell culture systems, BPC-157 at concentrations of 10 ng/mL to 1 µg/mL reduced NF-κB nuclear translocation by approximately 40–50%, with consequent reductions in TNF-α (30–45%) and IL-6 (25–40%) secretion. In inflamed bowel tissue from DSS-colitis rats, BPC-157 treatment reduced myeloperoxidase (MPO) activity — a marker of neutrophil infiltration — by approximately 50% versus vehicle at day 7 (p<0.01), confirming anti-inflammatory activity at the tissue level independent of in vitro findings.
Research Grade Specification: HPLC Purity, Endotoxin, and Lot Traceability Requirements
The reproducibility of BPC-157 preclinical data depends critically on material specification. The published literature reporting the biological activities summarized above was conducted predominantly with synthetic BPC-157 of HPLC purity >98–99%, confirmed by amino acid analysis and mass spectrometry (expected molecular ion [M+H]+ at 1420.6 Da). Endotoxin content <1 EU/mg is required to prevent LPS-mediated confounding of NF-κB, cytokine, and inflammatory endpoint measurements. Plasma t½ in rodents is estimated at 30–90 minutes based on functional endpoint recovery kinetics; direct pharmacokinetic plasma concentration studies using validated LC-MS/MS assays for this peptide are limited in the public literature due to the small molecular size and rapid tissue distribution. Alpha provides BPC-157 with full lot traceability, HPLC purity >99%, and lot-specific certificates of analysis. Alpha presents this content for research documentation purposes. All products are for research use only and not intended for clinical, diagnostic, or therapeutic use.